Lyra therapeutics announces publication of positive lantern results in the international forum of allergy & rhinology

Lyr-210 is the first drug-eluting product candidate to demonstrate statistically significant symptom improvement for six months with a single administration in surgically naÏve chronic rhinosinusitis patients

LYRA Ratings Summary

LYRA Quant Ranking